Cefepime: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>David E. Volk
imported>David E. Volk
mNo edit summary
Line 16: Line 16:


'''Cefepime''' is a fourth-generation [[cephalosporin]] [[antibiotic]] that was developed in 1994.  It has more activity than third-generation cephalosporins against Gram-postive and Gram-negative bacteria, and because of this, its use is typically reserved for severe [[nococomial]] [[pneumonia]], infections of a multi-resistant bacterial strain and the treatment of [[febrile]] [[neutropenia]].  It is indicated for the treatment of pneumonia caused by [[Streptococcus pneumoniae]], [[Pseudomonas aeruginosa]], [[Klebsiella pneumoniae]], or [[Enterobacter]] species and  also for empiric treatment of febrile neutropenic patients and urinary tract infections caused by [[Escherichia coli]] or [[Klebsiella pneumoniae]] for severe infections, or, when concurrent [[bacteremia]] is present, for milder infections of Escherichia coli, Klebsiella pneumoniae, or [[Proteus mirabilis]]. It is also used to treat skin and skin structure infections caused by methicillin-resistant strains of Staphylococcus aureus and Streptococcus pyogenes.  It also used in combination with [[metronidazole]] for complicated intra-abdominal infections caused by caused by many bacteria.
'''Cefepime''' is a fourth-generation [[cephalosporin]] [[antibiotic]] that was developed in 1994.  It has more activity than third-generation cephalosporins against Gram-postive and Gram-negative bacteria, and because of this, its use is typically reserved for severe [[nococomial]] [[pneumonia]], infections of a multi-resistant bacterial strain and the treatment of [[febrile]] [[neutropenia]].  It is indicated for the treatment of pneumonia caused by [[Streptococcus pneumoniae]], [[Pseudomonas aeruginosa]], [[Klebsiella pneumoniae]], or [[Enterobacter]] species and  also for empiric treatment of febrile neutropenic patients and urinary tract infections caused by [[Escherichia coli]] or [[Klebsiella pneumoniae]] for severe infections, or, when concurrent [[bacteremia]] is present, for milder infections of Escherichia coli, Klebsiella pneumoniae, or [[Proteus mirabilis]]. It is also used to treat skin and skin structure infections caused by methicillin-resistant strains of Staphylococcus aureus and Streptococcus pyogenes.  It also used in combination with [[metronidazole]] for complicated intra-abdominal infections caused by caused by many bacteria.
== Mechanism of action ==
Like other  cephalosporins and [[penicillin]]s, cefepime works by binding to specific [[penicillin binding proteins]] and thus inhibiting the last stage of bacterial cell wall synthesis (the peptidoglycan layer), leading to [[autolysis]] of the bacterial cells by autolyic enzymes such as [[autolysin]]s.  Whereas other cephalosporins and penicllins are degraded [[beta-lactamase]]s, cefepime is stable and is therefore a front line agent when infection with [[Enterobacteriaceae]] is known or suspected.
== Chemistry ==
Cefepime has the IUPAC chemical name (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]
-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, chemical formula C<sub>19</sub>H<sub>24</sub>N<sub>6</sub>O<sub>5</sub>S<sub>2</sub> and molecular mass 480.5611 g/mol.  It contains a [[beta-lactam]] moiety that is also present in other cephalosporins and [[penicillin]]s, but is much more stable against [[beta-lactamase]]s.
== Synonyms and brand names ==
Cefepime is also called cefepima in Spanish and cefepimum in Latin. It is sold under the brand names Maxcef®, Cepimax®, Cepimex® and Axepim®.
== External links ==
* {{CZMed}}

Revision as of 15:31, 5 April 2009

This article is developing and not approved.
 Main Article
 Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
https://en.citizendium.org/wiki/index.php?title=Cefepime&printable=yes
This editable Main Article is under development and subject to a disclaimer.
Cefepime.jpg
cefepime
IUPAC name: see chemistry section
Synonyms:
Formula: C19H24N6O5S2
 Uses: antibiotic drug
 Properties: beta-lactam
 Hazards: see drug interactions
Mass (g/mol): CAS #:
480.5611 88040-23-7


Cefepime is a fourth-generation cephalosporin antibiotic that was developed in 1994. It has more activity than third-generation cephalosporins against Gram-postive and Gram-negative bacteria, and because of this, its use is typically reserved for severe nococomial pneumonia, infections of a multi-resistant bacterial strain and the treatment of febrile neutropenia. It is indicated for the treatment of pneumonia caused by Streptococcus pneumoniae, Pseudomonas aeruginosa, Klebsiella pneumoniae, or Enterobacter species and also for empiric treatment of febrile neutropenic patients and urinary tract infections caused by Escherichia coli or Klebsiella pneumoniae for severe infections, or, when concurrent bacteremia is present, for milder infections of Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis. It is also used to treat skin and skin structure infections caused by methicillin-resistant strains of Staphylococcus aureus and Streptococcus pyogenes. It also used in combination with metronidazole for complicated intra-abdominal infections caused by caused by many bacteria.

Retrieved from "https://citizendium.org/wiki/index.php?title=Cefepime&oldid=453366"